ASSESSMENT OF POTENTIAL DRUG INTERACTIONS AMONG HOSPITALIZED PATIENTS IN NEUROLOGY DEPARTMENT IN TERTIARY CARE HOSPITALS
Objective: This research was instigated to determine and assess the prevalence, severity, type, and the total number of potential drug interactions in the neurology department of two hospitals in India.
Methods: The data were collected from the prescriptions and by patient history interview on a daily basis. The drug-drug interactions (DDIs) were identified using Micromedex® database-2.7 and drugs.com.
Results: The drug interactions were influenced by a plethora of risk factors: Gender, age, comorbidities, length of hospital stay, and the neurological condition. The study was comprised 320 patients, among 196 patients were identified with potential DDIs (PDDIs), and a total of 450 PDDIs were observed. The prevalence of PDDIs according to the severity was major (42.6%), moderate (45.11%), and minor (12.22%).
Conclusion: To lessen PDDIs, the range of medications for the patients must be properly managed, and it is encouraged to remove all medicines without therapeutic advantage, intention, and an indication.
2. Ahmad A, Khan MU, Haque I, Ivan R, Dasari R, Revanker M, et al. Evaluation of potential drug-drug interactions in general medicine ward of teaching hospital in Southern India. J Clin Diagn Res 2015;9:FC10 3.
3. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH, et al. Hospitalisations and emergency department visits due to drug-drug interactions: A literature review. Pharmacoepidemiol Drug Saf 2007;16:641-51.
4. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003;48:133-43.
5. Namazi S, Pourhatami S, Borhani-Haghighi A, Roosta S. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two Iranian teaching hospitals. Iran J Med Sci 2014; 39:515-21.
6. Gourie-Devi M. Epidemiology of neurological disorders in India: Review of background, prevalence and incidence of epilepsy, stroke, Parkinson’s disease and tremors. Neurol India 2014;62:588-98.
7. Shahabudin S, Bharti C, Faizal P. Surveillance of the potential drug-drug interactions in the medicine department of a tertiary care hospital. J Clin Diag Res 2012;6:1258-61.
8. Kashyap M, D’Cruz S, Sachdev A, Tiwari P. Drug-drug interactions and their predictors: Results from Indian elderly inpatients. Pharm Pract (Granada) 2013;11:191-5.
9. Bose D, Sushma M. Pattern and predictors of drug-drug interactions among the patients admitted in neurology at a tertiary care hospital-a cross-sectional study. Int J Pharm Sci Res 2016;7:3458-64.
10. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society of pacing and electrophysiology. Circulation 2001;104:2118-50.
11. Schedlbauer A, Prasad V, Mulvaney C, Phansalkar S, Stanton W, Bates DW, et al. What evidence supports the use of computerized alerts and prompts to improve clinicians’ prescribing behavior? J Am Med Inform Assoc 2009;16:531-8.
12. Lubinga SJ, Uwiduhaye E. Potential drug-drug interactions on in-patient medication prescriptions at Mbarara regional referral hospital (MRRH) in Western Uganda: Prevalence, clinical importance and associated factors. Afr Health Sci 2011;11:499-507.
13. Venkateswaramurthy N, Krishnaveni K, Freeda RM, Kumar RS. Assessment of potential drug–drug interaction in stroke patients. Int J Pharm Pharm Sci 2016;8:221-4.
14. Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005;165:2497-503.
15. Mantia G, Provenzano G. Rilevanza clinica delle interazioni farmacologiche di tipofarmacocinetico. Acta Med Mediterr 2008; 24:23 7.
16. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66.
17. Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Bozina N, Tomic S, et al. Adverse drug reactions caused by drug-drug interactions reported to Croatian agency for medicinal products and medical devices: A retrospective observational study. Croat Med J 2011;52:604 14.
18. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010;49:509-33.
19. Kameswaran R, Rajagopal SS, Kandasamy K, Krishnan K. pharmacist intervention on identification of drug interactions in tertiary care hospitals. Int J Pharm Pharm Sci 2018;10:23-9.
20. Ismail M. Drug-food interactions and role of the pharmacist. Asian J Pharm Clin Res 2009;2:81-91.
21. Bokor-Brati? M, Brkani? T. Clinical use of tetracyclines in the treatment of periodontal diseases. Med Pregl 2000;53:266-71.
22. Ogawa R, Echizen H. Clinically significant drug interactions with antacids: An update. Drugs 2011;71:1839-64.
23. Seedher N, Agarwal P. Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics. Drug Metabol Drug Interact 2010;25:17-24.
24. Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med 2013;8:205-10.
25. Phillips WA, Ratchford JM, Schultz JR. Effects of colestipol hydrochloride on drug absorption in the rat II. J Pharm Sci 1976; 65:1285 91.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.